Talazoparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor, primarily used in the treatment of specific types of cancer. PARP inhibitors like talazoparib exploit the concept of synthetic lethality by targeting cancer cells deficient in DNA repair mechanisms, particularly those with BRCA1 and BRCA2 mutations.
